ERBB2 and breast carcinoma: In particular, CD36-mediated metabolic adaptations have been implicated in lipid-dependent breast cancer aggressive phenotypes, including metastasis, resistance to HER2-targeted therapy and modulation of the tumor microenvironment by T-cell dysfunction (21, 23, 46–48).